Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonist
Phase 3Completed 2 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation
Trial Timeline
Feb 24, 2017 → Jun 6, 2019
NCT ID
NCT02866175About Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonist
Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonist is a phase 3 stage product being developed by Daiichi Sankyo for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT02866175. Target conditions include Atrial Fibrillation.
What happened to similar drugs?
20 of 20 similar drugs in Atrial Fibrillation were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02866175 | Phase 3 | Completed |
Competing Products
20 competing products in Atrial Fibrillation